Lite Strategy, Inc. (LITS) is a Healthcare stock trading at $1.00 (as of 2026-08-21), with a market capitalization of $34.02M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Lite Strategy, Inc. is a clinical-stage pharmaceutical company developing therapies for the treatment of cancer. The company focuses on developing novel and differentiated treatments, and it was formerly known as MEI Pharma, Inc. before changing its name in September 2025.
Lite Strategy, Inc. is a clinical-stage cancer drug developer, and in this quarter it generated revenue primarily from collaboration agreements (with no revenue from customers reported).
The profit engine is partnership-funded development, since the company reports collaboration agreement revenue while customer sales are effectively zero, and the operating business is deeply loss-making in the latest quarter.
| Collabs | $0.1B |
| Customers | $0.0B |
Business quality (Weak): Clear reliance on collaboration revenue in the reported quarter, but the operating result is extremely negative and customer revenue is not present yet, so near-term performance is hard to interpret from sales execution.
| Price | $1.00 |
| Market Cap | $34.02M |
| Price / Book | 0.60 |
| Price / Sales | 298.44 |
| FCF Yield | -54.0% |
| Revenue (TTM) | $0.00 |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | -189.5% |
| FCF Growth (YoY) | -58.7% |
| Altman Z-Score | -17.19 (distress) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| Top Institutional Holder | RENAISSANCE TECHNOLOGIES LLC ($2.02M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Anne Frese |
| Employees | 4 |
| Country | US |
| IPO Date | 2003-12-18 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.